Development of bivalent oleanane-type triterpenes as potent HCV entry inhibitors

European Journal of Medicinal Chemistry

Volumn 77, Issue , 2014, Pages 258-268

  Yu, Fei ^a,c   Peng, Yiyun ^a   Wang, Qi ^a   Shi, Yongying ^a   Si, Longlong ^a   Wang, Han ^a   Zheng, Yongxiang ^a   Lee, Emily ^b   Xiao, Sulong ^a   Yu, Maorong ^a   Li, Yingbo ^a   Zhang, Chuanling ^a   Tang, Hengli ^b   Wang, Chunguang ^a   Zhang, Lihe ^a   Zhou, Demin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b FLORIDA STATE UNIVERSITY   (United States)

^c KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Dimer; Echinocystic acid; HCV entry inhibitor; Triterpene

Indexed keywords

1,2,3 TRI [[N (3BETA,16ALPHA DIHYDROXYL OLEAN 12 EN 28 OYL)AMINO]METHYL (1H 1,2,3 TRIAZOL 4 YL)]PROPANE; 2,2,2 TRI [[N (3BETA,16ALPHA DIHYDROXYL OLEAN 12 EN 28 OYL)AMINO]METHYL (1H 1,2,3 TRIAZOL 4 YL)METHYL]ETHANOL; ANTIVIRUS AGENT; ECHINOCYSTIC ACID; N (3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) (1 BENZYL 1H 1,2,3 TRIAZOL 4 YL)METHYLAMINE; N (3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) (1 ETHYL 1H 1,2,3 TRIAZOL 4-YL)METHYLAMINE; N (3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) (1 PROPYL 1H 1,2,3 TRIAZOL 4 YL)METHYLAMIN; N (3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1 (3 HYDROXYPROPYL) 1H 1,2,3 TRIAZOL 4 YL]METHYLAMINE; N (3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28- YL) [1 (2 HYDROXYETHYL) 1H 1,2,3 TRIAZOL 4 YL]METHYLAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) 1,12 DIAMINODODECANE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) 1,3 DIAMINOPROPANE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) 1,4 DIAMINOBUTANE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) 1,5 DIAMINE 3 OXAPENTANE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) 1,6 DIAMINOHEXANE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' (ETHANE 1,2 DIYL)BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' (HEXANE 1,6 DIYL)BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' (PENTANE 1,5 DIYL)BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' (PROPANE 1,4 DIYL)BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' [(2,5 DIMETHOXY 1,4 PHENYLENE)BIS(METHYLENE)]BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' [(2,5 DIMETHYL 1,4 PHENYLENE)BIS(METHYLENE)]BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' [1,2 PHENYLENEBIS(METHYLENE)]BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' [1,3 PHENYLENEBIS(METHYLENE)]BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' [1,4 PHENYLENEBIS(ETHANE 2,1 DIYL)]BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' [OXYBIS(ETHANE 2,1DIYL)](1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL) [1,1' [[[OXYBIS(ETHANE 2,1DIYL)]BIS(OXY)]BIS(ETHANE 2,1 DIYL)]BIS(1H 1,2,3 TRIAZOLE 4,1 DIYL)]DIMETHANAMINE; N,N' BIS(3BETA,16ALPHA DIHYDROXY OLEAN 12 EN 28 OYL)TETRAETHYLENE GLYCOL BISAMINE; TETRA [[N (3BETA,16ALPHA DIHYDROXYL OLEAN 12 EN 28 OYL)AMINO]METHYL (1H 1,2,3 TRIAZOL 4 YL)METHYL]METHANE; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; OLEANANE; OLEANOLIC ACID; TRITERPENE;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DEVELOPMENT; DRUG POTENCY; HEMOLYSIS; HEPATITIS C VIRUS; HYDROPHILICITY; HYDROPHOBICITY; IC 50; NONHUMAN; RIGIDITY; SURFACE PLASMON RESONANCE; VIRUS ENTRY; ANALOGS AND DERIVATIVES; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; HEPACIVIRUS; HUMAN; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HEPACIVIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; OLEANOLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TRITERPENES; VIRUS INTERNALIZATION;

EID: 84896536482     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.03.017     Document Type: Article

References (18)

1. A.J. Rodger, S. Roberts, A. Lanigan, S. Bowden, T. Brown, N. Crofts, Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975, Hepatology 32 (2000) 582-587.
2. T. Sy, M.M. Jamal, Epidemiology of hepatitis C virus (HCV) infection, International Journal of Medical Sciences 3 (2006) 41-46.
3. C. Sheridan, New Merck and Vertex drugs raise standard of care in hepatitis C, Nature Biotechnology 29 (2011) 553-554.
4. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, F.L. Gonçales, D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman, J. Yu, Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection, The New England Journal of Medicine 347 (2002) 975-982.
5. A.M. Di Bisceglie, J. McHutchison, C.M. Rice, New therapeutic strategies for hepatitis C, Hepatology 35 (2002) 224-231. (Pubitemid 34032564)
6. P. Halfon, S. Locarnini, Hepatitis C virus resistance to protease inhibitors, Journal of Hepatology 55 (2011) 192-206.
7. P. Halfon, C. Sarrazin, Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Liver International 32 (2012) 79-87.
8. J. Yang, D. Zhou, F. Wong-Staal, Screening of small-molecule compounds as inhibitors of HCV entry, Methods in Molecular Biology 510 (2009) 295-304.
9. R. Schinazi, L. Bassit, C. Gavegnano, HCV drug discovery aimed at viral eradication, Journal of Viral Hepatitis 17 (2010) 77-90.
10. S. Xiao, Q. Wang, F. Yu, Y. Peng, M. Yang, M. Sollogoub, P. Sinaÿ, Y. Zhang, L. Zhang, D. Zhou, Conjugation of cyclodextrin with fullerene as a new class of HCV entry inhibitors, Bioorganic & Medicinal Chemistry 20 (2012) 5616-5622.
11. C.J. Baldick, M.J. Wichroski, A. Pendri, A.W. Walsh, J. Fang, C.E. Mazzucco, K.A. Pokornowski, R.E. Rose, B.J. Eggers, M. Hsu, A novel small molecule inhibitor of Hepatitis C virus entry, PLOS Pathogens 6 (2010) e1001086.
12. F. Yu, Q. Wang, Z. Zhang, Y. Peng, Y. Qiu, Y. Shi, Y. Zheng, S. Xiao, H. Wang, X. Huang, L. Zhu, K. Chen, C. Zhao, C. Zhang, M. Yu, D. Sun, L. Zhang, D. Zhou, Development of oleanane-type triterpenes as a new class of HCV entry inhibitors, Journal of Medicinal Chemistry 56 (2013) 4300-4319.
13. H. Wang, Q. Wang, S. Xiao, F. Yu, M. Ye, Y. Zheng, C. Zhao, D. Sun, L. Zhang, D. Zhou, Elucidation of the pharmacophore of echinocystic acid, a new lead for blocking HCV entry, European Journal of Medicinal Chemistry 64 (2013) 160-168.
14. P. Pileri, Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A.J. Weiner, M. Houghton, D. Rosa, G. Grandi, Binding of hepatitis C virus to CD81, Science 282 (1998) 938-941. (Pubitemid 28507525)
15. D. Soriano del Amo, W. Wang, H. Jiang, C. Besanceney, A.C. Yan, M. Levy, Y. Liu, F.L. Marlow, P. Wu, Biocompatible copper (I) catalysts for in vivo imaging of glycans, Journal of the American Chemical Society 132 (2010) 16893-16899.
16. S. Liu, C.A. Nelson, L. Xiao, L. Lu, P.P. Seth, D.R. Davis, C.H. Hagedorn, Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase, Antiviral Research 89 (2011) 54-63.
17. G. Francis, Z. Kerem, H.P.S. Makkar, K. Becker, The biological action of saponins in animal systems: a review, British Journal of Nutrition 88 (2002) 587-605. (Pubitemid 36082888)
18. G. Luo, R. Colonno, M. Krystal, Characterization of a hemagglutinin-specific inhibitor of influenza A virus, Virology 226 (1996) 66-76. (Pubitemid 26414395)